Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Jun;59(6):404–407. doi: 10.1136/ard.59.6.404

Anti-TNFα: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

J BRAUN 1, J SIEPER 1
PMCID: PMC1753169  PMID: 10834852

Full Text

The Full Text of this article is available as a PDF (116.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amor B., Dougados M., Khan M. A. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am. 1995 Feb;21(1):117–128. [PubMed] [Google Scholar]
  2. Amor B., Santos R. S., Nahal R., Listrat V., Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol. 1994 Oct;21(10):1883–1887. [PubMed] [Google Scholar]
  3. Beutler B. A. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl. 1999 May;57:16–21. [PubMed] [Google Scholar]
  4. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., Eggens U., Distler A., Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995 Apr;38(4):499–505. doi: 10.1002/art.1780380407. [DOI] [PubMed] [Google Scholar]
  5. Braun J., Bollow M., Seyrekbasan F., Häberle H. J., Eggens U., Mertz A., Distler A., Sieper J. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996 Apr;23(4):659–664. [PubMed] [Google Scholar]
  6. Braun J., Bollow M., Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):697–735. doi: 10.1016/s0889-857x(05)70038-7. [DOI] [PubMed] [Google Scholar]
  7. Braun J., Tuszewski M., Ehlers S., Häberle J., Bollow M., Eggens U., Distler A., Sieper J. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol. 1997 Jun;24(6):1101–1105. [PubMed] [Google Scholar]
  8. Breban M., Gombert B., Amor B., Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum. 1999 Mar;42(3):580–581. doi: 10.1002/1529-0131(199904)42:3<580::AID-ANR27>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  9. Calin A., Nakache J. P., Gueguen A., Zeidler H., Mielants H., Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999 Sep;38(9):878–882. doi: 10.1093/rheumatology/38.9.878. [DOI] [PubMed] [Google Scholar]
  10. Carette S., Graham D., Little H., Rubenstein J., Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. 1983 Feb;26(2):186–190. doi: 10.1002/art.1780260210. [DOI] [PubMed] [Google Scholar]
  11. Charles P., Elliott M. J., Davis D., Potter A., Kalden J. R., Antoni C., Breedveld F. C., Smolen J. S., Eberl G., deWoody K. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999 Aug 1;163(3):1521–1528. [PubMed] [Google Scholar]
  12. Cope A. P. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 1998 Dec;10(6):669–676. doi: 10.1016/s0952-7915(98)80087-3. [DOI] [PubMed] [Google Scholar]
  13. Corral L. G., Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I107–I113. doi: 10.1136/ard.58.2008.i107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. De Vos M., Cuvelier C., Mielants H., Veys E., Barbier F., Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology. 1989 Feb;96(2 Pt 1):339–344. doi: 10.1016/0016-5085(89)91557-6. [DOI] [PubMed] [Google Scholar]
  15. Doherty M. The misconduct of redundant publication. Ann Rheum Dis. 1996 Nov;55(11):783–785. doi: 10.1136/ard.55.11.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dougados M., Gueguen A., Nakache J. P., Velicitat P., Veys E. M., Zeidler H., Calin A. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999 Mar;38(3):235–244. doi: 10.1093/rheumatology/38.3.235. [DOI] [PubMed] [Google Scholar]
  17. Gran J. T., Skomsvoll J. F. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul;36(7):766–771. doi: 10.1093/rheumatology/36.7.766. [DOI] [PubMed] [Google Scholar]
  18. Kavanaugh A. F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. doi: 10.1016/s0889-857x(05)70028-4. [DOI] [PubMed] [Google Scholar]
  19. Langman M. J., Jensen D. M., Watson D. J., Harper S. E., Zhao P. L., Quan H., Bolognese J. A., Simon T. J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999 Nov 24;282(20):1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
  20. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):737-51, viii. doi: 10.1016/s0889-857x(05)70039-9. [DOI] [PubMed] [Google Scholar]
  21. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  22. Maksymowych W. P., Jhangri G. S., Leclercq S., Skeith K., Yan A., Russell A. S. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol. 1998 Apr;25(4):714–717. [PubMed] [Google Scholar]
  23. McGonagle D., Gibbon W., Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998 Oct 3;352(9134):1137–1140. doi: 10.1016/S0140-6736(97)12004-9. [DOI] [PubMed] [Google Scholar]
  24. Moreland L. W. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May;57:7–15. [PubMed] [Google Scholar]
  25. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Ishida H., Shimizu M., Suemura M., McCloskey R., Kishimoto T. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol. 1999 Sep;19(5):305–313. doi: 10.1023/a:1020543625282. [DOI] [PubMed] [Google Scholar]
  26. Paleolog E. M., Hunt M., Elliott M. J., Feldmann M., Maini R. N., Woody J. N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1082–1091. doi: 10.1002/art.1780390703. [DOI] [PubMed] [Google Scholar]
  27. Pennanen N., Lapinjoki S., Urtti A., Mönkkönen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res. 1995 Jun;12(6):916–922. doi: 10.1023/a:1016281608773. [DOI] [PubMed] [Google Scholar]
  28. Present D. H., Rutgeerts P., Targan S., Hanauer S. B., Mayer L., van Hogezand R. A., Podolsky D. K., Sands B. E., Braakman T., DeWoody K. L. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398–1405. doi: 10.1056/NEJM199905063401804. [DOI] [PubMed] [Google Scholar]
  29. Sandborn W. J., Hanauer S. B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119–133. doi: 10.1097/00054725-199905000-00008. [DOI] [PubMed] [Google Scholar]
  30. Spoorenberg A., de Vlam K., van der Heijde D., de Klerk E., Dougados M., Mielants H., van der Tempel H., Boers M., van der Linden S. Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol. 1999 Apr;26(4):997–1002. [PubMed] [Google Scholar]
  31. Van den Bosch F., Kruithof E., Baeten D., De Keyser F., Mielants H., Veys E. M. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433. doi: 10.1136/ard.59.6.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ward M. M. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999 Aug;12(4):247–255. [PubMed] [Google Scholar]
  33. Ward M. M., Kuzis S. Treatments used by patients with ankylosing spondylitis comparison with the treatment preferences of rheumatologists. J Clin Rheumatol. 1999 Feb;5(1):1–8. doi: 10.1097/00124743-199902000-00001. [DOI] [PubMed] [Google Scholar]
  34. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  35. Zink A., Braun J., Listing J., Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000 Mar;27(3):613–622. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES